IBIO Key Stats
- IBIO, INC. Files SEC form 10-Q, Quarterly Report May 20
- IBIO, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, F... May 1
- iBio, Inc. closes $4.2 million public offering and terminates At-the-market offe... Apr 29
- IBIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Finan... Apr 23
- iBio (IBIO) Prices 8,925,000 Units at $0.48 Each Street Insider Apr 23
- iBio, Inc. Prices $4.2 Million Public Offering PR Newswire Apr 23
- iBio, Inc. (IBIO) Announces Offering of Common Stock and Warrants Street Insider Apr 22
- iBio files to sell common stock and common stock purchase warrants Apr 22
- iBio Announces Proposed Public Offering Benzinga Apr 22
- IBIO, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Conti... Apr 22
IBIO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). iBio is down 70.16% over the last year vs S&P 500 Total Return up 31.59%, Acura Pharmaceuticals down 9.09%, and Horizon Pharma down 37.11%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for IBIO
Pro Report PDF for IBIO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download IBIO Pro Report PDF
Pro Strategies Featuring IBIO
Did iBio make it into our Pro Portfolio Strategies?